Though the new study was more comprehensive than past research because it looked at patients over the course of three years, research since November 2000 has suggested that those who take Vioxx face a heart attack risk four to five times greater than those who take older, equally effective arthritis treatments such as ibuprofen and naproxen.
Now research lab director Peter Kim and general counsel Kenneth Frazier were flying to Boston to tell one of the men most responsible for Vioxx's success that Merck would be pulling the drug in two days.
